Type of prostate cancer-Adenocarcinoma - Page 2 of 19 Posts on Medivizor
Navigation Menu

Type of prostate cancer-Adenocarcinoma Posts on Medivizor

Comparing the survival outcomes of pembrolizumab with or without enzalutamide in men with previously untreated metastatic castration-resistant prostate cancer.

Comparing the survival outcomes of pembrolizumab with or without enzalutamide in men with previously untreated metastatic castration-resistant prostate cancer.

Posted by on Jun 12, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the survival and safety outcomes of pembrolizumab (Keytruda; PEM) plus enzalutamide (Xtandi; ENZ) combination versus pembrolizumab alone in patients with previously untreated metastatic castration-resistant prostate cancer (mCRPC). The data showed that PEM plus ENZ combination was associated with increased survival...

Read More

Comparing the outcomes of robot‑assisted and laparoscopic radical prostatectomy for the treatment of localized prostate cancer.

Comparing the outcomes of robot‑assisted and laparoscopic radical prostatectomy for the treatment of localized prostate cancer.

Posted by on Jun 6, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the outcomes of robotic-assisted radical prostatectomy (RARP) with standard laparoscopic radical prostatectomy (LRP) for the treatment of patients with localized prostate cancer. The study found that the RARP approach was associated with better outcomes compared to LRP. Some background Localized prostate cancer (PCa)...

Read More

Comparing the outcomes of Retzius-sparing versus standard robotic prostate surgery for the treatment of localized prostate cancer.

Comparing the outcomes of Retzius-sparing versus standard robotic prostate surgery for the treatment of localized prostate cancer.

Posted by on May 6, 2021 in Prostate cancer | 0 comments

In a nutshell This study compared the outcomes of Retzius-sparing (RS) robotic-assisted laparoscopic prostatectomy (RALP) with standard RALP (sRALP) for the treatment of patients with localized prostate cancer (PCa). The study found that the RS-RALP approach may be associated with better urinary outcomes compared to sRALP. Some background...

Read More

Evaluating the combination of sipuleucel-T with radium-223 in men with metastatic castration-resistant prostate cancer spread to the bone.

Evaluating the combination of sipuleucel-T with radium-223 in men with metastatic castration-resistant prostate cancer spread to the bone.

Posted by on May 3, 2021 in Prostate cancer | 0 comments

In a nutshell The study investigated the effectiveness of combining sipuleucel-T (Provenge) with radium-223 (Xofigo) therapy in men with castration-resistant prostate cancer (CRPC) that has spread to the bones. The key finding was that the combination therapy improved the survival rates of these patients.  Some background Prostate cancer often...

Read More

Which hormonal therapy should be first in patients with castration-resistant metastatic prostate cancer?

Which hormonal therapy should be first in patients with castration-resistant metastatic prostate cancer?

Posted by on Apr 18, 2021 in Prostate cancer | 0 comments

In a nutshell This study analyzed and evaluated which hormonal therapy should be given first, abiraterone acetate (Zytiga) plus prednisone (Deltasone) (AAP) or enzalutamide (Xtandi; ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC). The data showed that AAP followed by ENZ is more effective in delaying...

Read More

Evaluating photoselective vaporization for urinary symptoms in patients with prostate cancer on active surveillance.

Evaluating photoselective vaporization for urinary symptoms in patients with prostate cancer on active surveillance.

Posted by on Mar 21, 2021 in Prostate cancer | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of photoselective vaporization of the prostate (PVP) in patients with prostate cancer with lower urinary tract symptoms (LUTS) during active surveillance. The results suggested that PVP treatment was safe and effective in these patients. Some background Active surveillance (AS)...

Read More

Evaluating the outcomes of salvage Retzius-sparing robotic-assisted radical prostatectomy

Evaluating the outcomes of salvage Retzius-sparing robotic-assisted radical prostatectomy

Posted by on Mar 6, 2021 in Prostate cancer | 0 comments

In a nutshell This study investigated the effectiveness and functional outcomes of using the Retzius-sparing robotic-assisted radical prostatectomy (RS-RARP) as a salvage treatment for patients with localized prostate cancer (PCa). The study found that the sRS-RARP approach was associated with good urinary and oncological outcomes in these...

Read More

Evaluating the long-term outcomes of regional (hockey-stick) prostate cryoablation in men with low- or intermediate-risk prostate cancer

Evaluating the long-term outcomes of regional (hockey-stick) prostate cryoablation in men with low- or intermediate-risk prostate cancer

Posted by on Feb 27, 2021 in Prostate cancer | 0 comments

In a nutshell This study reported the long-term effectiveness and quality of life outcomes after prostate cryoablation (a process that uses extreme cold to destroy prostate tumor) treatment for patients with low and intermediate-risk prostate cancer (PCa). The data showed that the treatment had good outcomes with minimal impact on urinary and sexual...

Read More

Evaluating combination therapies for metastatic hormone-sensitive prostate cancer.

Evaluating combination therapies for metastatic hormone-sensitive prostate cancer.

Posted by on Jan 17, 2021 in Prostate cancer | 0 comments

In a nutshell This study was carried out to look at the use of combining radiotherapy (RT), systemic therapy (ST; whole-body treatment), and androgen deprivation therapy (ADT) for prostate cancer (PC) that is hormone-sensitive and has spread. The authors concluded that ADT plus RT led to better outcomes in patients with low-volume disease. Some...

Read More

Evaluating the effects of abiraterone acetate in combination with androgen deprivation therapy for the treatment of metastatic hormone-sensitive prostate cancer.

Evaluating the effects of abiraterone acetate in combination with androgen deprivation therapy for the treatment of metastatic hormone-sensitive prostate cancer.

Posted by on Jan 10, 2021 in Prostate cancer | 0 comments

In a nutshell This study examined the effects of abiraterone acetate (AA; Zytiga) in combination with androgen deprivation therapy (ADT) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC). The data showed that AA and ADT combination improves the outcomes in these patients. Some background Patients with mHSPC have...

Read More

Evaluating cabozantinib plus docetaxel and prednisone in patients with metastatic castration resistant prostate cancer

Evaluating cabozantinib plus docetaxel and prednisone in patients with metastatic castration resistant prostate cancer

Posted by on Nov 15, 2020 in Prostate cancer | 0 comments

In a nutshell The study evaluated outcomes of combining cabozantinib (Cabometyx) with docetaxel (Taxotere) and prednisone (Deltasone) in treating patients with metastatic castration-resistant prostate cancer (mCRPC). The main finding was that the combination was safe and could possibly be effective in such patients. Some background Docetaxel was the...

Read More
ABOUT USHOW IT WORKSBLOG NEWS PARTNERS CONTACT US PRIVACY POLICY TERMS OF USE
FROM OUR BLOG
LATEST NEWS
CONNECT WITH US
© 2024 Medivizor